ProKidney Corp. Class A Ordinary Shares

PROKNASDAQ • USD
1.30 USD
↘ 0.18 (11.90%)AT CLOSE (03:59 PM EDT)
1.33
↗ 0.03 (2.32%)
POST MARKET (AS OF 04:14 PM EDT)
Post Market
AS OF 04:14 PM EDT
1.33
↗ 0.03 (2.32%)
🔴Market: CLOSED

ProKidney Corp. Class A Ordinary Shares (PROK) trades at $1.30 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation front, PROK trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Oct 30, 2026.

Open?$1.41
High?$1.46
Low?$1.29
Prev. Close?$1.47
Volume?1.7M
Avg. Volume?1.2M
VWAP?$1.36
Rel. Volume?1.41x
Bid / Ask
Bid?$1.31 × 300
Ask?$1.40 × 100
Spread?$0.09
Midpoint?$1.36
Valuation & Ratios
Market Cap?271.7M
Shares Out?208.9M
Float?89.7M
Float %?42.9%
P/E Ratio?N/A
P/B Ratio?-0.31
EPS?-$0.40
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Employees
231
Market Cap
307.1M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2022-07-12
Address
2000 FRONTIS PLAZA BLVD.
WINSTON-SALEM, NC 27103
Phone: 336-999-7028
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
14
Short Sent.?
10
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.73Distress
Confidence?76%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?27.40%Squeeze Risk
Short Interest?24.6M
Days to Cover?20.8
Free Float89.7M
Avg Daily Volume1.2M
Settlement Date2026-10-15
Financial Health
Current Ratio?8.36Strong
Quick Ratio?8.36Strong
Cash Ratio?3.30Strong
Debt/Equity?-0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
S&P
97
-0.31CHEAP▾
P/S?
Peers
100
S&P
3
332.11HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.2CHEAP▾
EV/Sales?
Peers
100
S&P
3
240.59HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
32
9.5%FAIR▾
ROA?
S&P
3
-33.8%WEAK▾
Cash Flow & Enterprise
FCF?$-159734000
Enterprise Value?$196.8M
Fundamentals ratios updated end of day